The absolute and relative content of T- and B-lymphocytes, T-helpers (CD4), T-suppressors (CD8), phagocytosis, complement and immunoglobulins A, M, G in the blood serum was examined in patients with chronic purulent otitis media. The investigation also involved tests on immunological activity of tymoptin (T), sodium nucleinate (SN), prodigiosan (PR), the combination of SN with PR. 148 patients aged 15-56 years were subdivided into 5 groups. In pretreatment immunological status of all the patients the count of T- and B-lymphocytes, T-helpers, phagocytosis were reduced against increased counts of IgM and T-suppressora. All the patients received similar conventional treatment with adjuvant SN (group 2), PR (group III), SN + PR (group 4), T (group 5). The conventional conservative and especially surgical treatment aggravated immunodeficiency. The adjuvant immunocorrectors potentiated the treatment effects which appeared to be most beneficial in group V followed by by groups IV, II and III in diminishing order.

Download full-text PDF

Source

Publication Analysis

Top Keywords

patients chronic
8
b-lymphocytes t-helpers
8
group group
8
patients
5
group
5
[correction immunologic
4
immunologic disorders
4
disorders patients
4
chronic suppurative
4
suppurative otitis
4

Similar Publications

Background: Dysregulated GABA/somatostatin (SST) signaling has been implicated in psychiatric and neurodegenerative disorders. The inhibition of excitatory neurons by SST+ interneurons, particularly through α5-containing GABAA receptors (α5-GABAAR), plays a crucial role in mitigating cognitive functions. Previous research demonstrated that an α5-positive allosteric modulator (α5-PAM) mitigates working memory deficits and reverses neuronal atrophy in aged mice.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

NYU Grossman School of Medicine, New York, NY, USA; NYU, New York City, NY, USA.

Background: Astrocytes, a major glial cell in the central nervous system (CNS), can become reactive in response to inflammation or injury, and release toxic factors that kill specific subtypes of neurons. Over the past several decades, many groups report that reactive astrocytes are present in the brains of patients with Alzheimer's disease, as well as several other neurodegenerative diseases. In addition, reactive astrocyte sub-types most associated with these diseases are now reported to be present during CNS cancers of several types.

View Article and Find Full Text PDF

Background: Seizures in Alzheimer's Disease (AD) are increasingly recognized to occur and can increase cognitive decline and reduce survival compared to unaffected age-matched peers (Lyou et al. 2018). Administration of antiseizure medicines (ASMs) to AD patients with epileptiform activity may improve cognition (Vossel et al.

View Article and Find Full Text PDF

Background: Early-onset Alzheimer's disease (EOAD) associated with amyloid precursor protein (APP) duplications or presenilin (PSEN) variants increases risk of seizures. Targeting epileptiform activity with antiseizure medicine (ASM) administration to AD patients may beneficially attenuate cognitive decline (Vossel et al, JAMA Neurology 2021). However, whether mechanistically distinct ASMs differentially suppress seizures in discrete EOAD models is understudied (Lehmann et al, Neurochem Res 2021).

View Article and Find Full Text PDF

Background: There are no cures for Alzheimer's disease (AD), a progressive neurodegenerative disorder characterized by elevation of beta-amyloid and tau proteins besides neuronal death and causing cognitive impairment. Phosphodiesterase 5 (PDE5) is a cyclic guanosine monophosphate-degrading enzyme involved in numerous biological pathways including those relevant to memory formation. PDE5 inhibition offers the potential to attenuate AD progression by acting at the downstream level of beta-amyloid and tau elevation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!